While the relatively low prevalence of hormone receptor positivity in this study suggests that Nigerian patients with ovarian cancer may benefit less from hormone receptor antagonists, further studies utilizing large patient cohorts may be required. The gene discussed is NR4A1; the disease is ovarian carcinoma.